Method for changing condition of eyelid of hairless animal

Abstract

A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.

1 . A method for changing a condition of an eyelid of a hairless animal comprising restricting an intake of at least one of a lipid and a mineral by the hairless animal. 
     
     
         2 . The method according to  claim 1 , wherein a change in the condition of the eyelid is at least one of plugging of meibomian gland orifices and telangiectasia around meibomian gland orifices. 
     
     
         3 . The method according to  claim 1 , wherein the hairless animal is a hairless mouse or a hairless rat. 
     
     
         4 . The method according to  claim 1 , wherein the hairless animal is a Hos:HR-1 hairless mouse. 
     
     
         5 . The method according to  claim 1 , wherein the lipid of which intake is restricted is an essential fatty acid. 
     
     
         6 . The method according to  claim 5 , wherein the essential fatty acid of which intake is restricted is linoleic acid or adinolenic acid. 
     
     
         7 . The method according to  claim 1 , wherein the mineral of which intake is restricted is magnesium. 
     
     
         8 . The method according to  claim 1 , wherein the intake of the lipid is restricted to 3 mg/kg/day or less. 
     
     
         9 . The method according to  claim 7 , wherein the intake of magnesium is restricted to 0.15 mg/kg/day or less. 
     
     
         10 . The method according to  claim 1 , wherein the intake of at least one of the lipid and the mineral is restricted by giving an HR-AD diet. 
     
     
         11 . The method according to  claim 1 , wherein a period during which the intake of at least one of the lipid and the mineral is restricted is 3 days or longer. 
     
     
         12 . A model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method according to  claim 1 . 
     
     
         13 . The model animal according to  claim 12 , wherein the eyelid disease is a disease involving at least one of plugging of meibomian gland orifices and telangiectasia around meibomian gland orifices. 
     
     
         14 . The model animal according to  claim 12 , wherein the eyelid disease is blepharitis, marginal blepharitis, meibomian gland dysfunction, meibomitis, or meibomian gland blockage. 
     
     
         15 . A method for producing a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease by the method according to  claim 1 . 
     
     
         16 . A method of screening for a substance having a therapeutic or prophylactic effect against an eyelid disease comprising administering a test substance to the model animal according to  claim 12 , and determining a condition of an eyelid of the model animal. 
     
     
         17 . The method of screening according to  claim 16 , wherein the condition of the eyelid is a condition of meibomian glands or therearound. 
     
     
         18 . The method of screening according to  claim 17 , wherein the condition of meibomian glands or therearound is at least one of plugging of meibomian gland orifices and telangiectasia around meibomian gland orifices. 
     
     
         19 . The method of screening according to  claim 16 , wherein the test substance is instilled into an eye. 
     
     
         20 . A substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening according to  claim 16 . 
     
     
         21 . A therapeutic or prophylactic agent against an eyelid disease containing the substance according to  claim 20  as an active ingredient.